Table 1.

Clinicopathologic correlation of AIB1 expression in cervical cancer.

		AIB1 expression		P value a
Variables	All cases	High expression	Low expression
Age b				0.350
≤50	75	41(39.6)	34(35.4)
>50	33	16(17.4)	17(15.6)
WHO grade				0.925
G1	49	25(25.9)	24(23.1)
G2	38	21(20.1)	17(17.9)
G3	21	11(11.1)	10(9.9)
FIGO stage				0.003
II stage	32	9(16.9)	23(15.1)	III vs IV=0.465
III stage	42	25(22.2)	17(19.8)	II vs IV=0.001
IV stage	34	23(17.9)	11(16.1)	II vs III=0.007
T status				0.027
T2	37	13(19.5)	24(17.5)	T3 vs T4=0.065
T3	45	27(23.8)	18(21.3)	T2 vs T4=0.018
T4	26	17(13.7)	9(12.3)	T2 vs T3=0.025
N status				0.021
N0	71	32(37.5)	39(33.5)
N1	37	25(19.5)	12(17.5)
M status				0.015
M0	82	38(43.3)	44(38.7)
M1	26	19(13.7)	7(12.3)
CRT response				0.014
CR	46	18(24.3)	28(21.7)
Non-CR	62	39(32.7)	23(29.3)

^a Chi-square test; ^b Median age;

T status: T stages; N status: lymph nodes status; M status: Distant metastasis;

CR: Complete response/complete remission; CRT: chemoradiotherapy; P: P value;